We are live on ! Find out more
SGAM

Smith Group Asset Management Portfolio holdings

AUM $2.46B
1-Year Est. Return 57.16%
This Fund
S&P 500
This Quarter Est. Return
+9.97%
1 Year Est. Return
+57.16%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$2.99B
AUM Growth
-$263M
Cap. Flow
-$458M
Cap. Flow %
-15.28%
Top 10 Hldgs %
28.23%
Holding
498
New
54
Increased
54
Reduced
221
Closed
53

Top Buys

Rank Stock Value
1
BA icon
Boeing
BA
+$63.6M
2
TNL icon
Travel + Leisure Co
TNL
+$47.7M
3
PG icon
Procter & Gamble
PG
+$26.9M
4
BIIB icon
Biogen
BIIB
+$24.9M
5
HLT icon
Hilton Worldwide
HLT
+$22.5M

Sector Composition

Rank Sector Weight
1 Technology 20.6%
2 Consumer Discretionary 17.81%
3 Healthcare 15.25%
4 Industrials 13.39%
5 Communication Services 9.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MFC icon
201
Manulife Financial
MFC
$73.3B
$590K 0.02%
29,100
ACN icon
202
Accenture
ACN
$109B
$589K 0.02%
4,360
CM icon
203
Canadian Imperial Bank of Commerce
CM
$109B
$582K 0.02%
13,292
BPMC
204
DELISTED
Blueprint Medicines
BPMC
$575K 0.02%
+8,250
New +$441K
OMAB icon
205
Grupo Aeroportuario Centro Norte
OMAB
$5.24B
$558K 0.02%
12,560
SHI
206
DELISTED
Sinopec Shanghai Petrochemical Co., Ltd.
SHI
$537K 0.02%
8,980
LGND icon
207
Ligand Pharmaceuticals
LGND
$6.42B
$534K 0.02%
6,284
VAC icon
208
Marriott Vacations Worldwide
VAC
$3.89B
$532K 0.02%
4,270
+655
+18% +$75.4K
FFIN icon
209
First Financial Bankshares
FFIN
$4.93B
$519K 0.02%
22,984
+3,504
+18% +$73.4K
TLK icon
210
Telkom Indonesia
TLK
$14.7B
$519K 0.02%
15,120
AVXS
211
DELISTED
AveXis, Inc. Common Stock
AVXS
$516K 0.02%
+5,330
New +$481K
PTLA
212
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$511K 0.02%
9,460
DAN icon
213
Dana Inc
DAN
$3.21B
$478K 0.02%
17,096
+2,585
+18% +$62.7K
FOLD
214
DELISTED
Amicus Therapeutics
FOLD
$474K 0.02%
31,400
BLUE
215
DELISTED
bluebird bio
BLUE
$470K 0.02%
264
HALO icon
216
Halozyme
HALO
$12.2B
$469K 0.02%
26,980
ONCE
217
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$457K 0.02%
+5,130
New +$390K
RARE icon
218
Ultragenyx Pharmaceutical
RARE
$2.64B
$455K 0.02%
8,550
TMHC
219
DELISTED
Taylor Morrison
TMHC
$447K 0.01%
20,286
+3,103
+18% +$68.6K
PRTA icon
220
Prothena Corp
PRTA
$468M
$437K 0.01%
6,740
IRWD icon
221
Ironwood Pharmaceuticals
IRWD
$669M
$432K 0.01%
32,692
HOMB icon
222
Home BancShares
HOMB
$6.17B
$431K 0.01%
17,095
-53,455
-76% -$1.28M
SAGE
223
DELISTED
Sage Therapeutics
SAGE
$426K 0.01%
6,840
SRPT icon
224
Sarepta Therapeutics
SRPT
$1.81B
$415K 0.01%
9,160
LOXO
225
DELISTED
Loxo Oncology, Inc
LOXO
$408K 0.01%
+4,430
New +$344K

Similar funds

Smith Group Asset Management's Q3 2017 Portfolio in Review

As of Q3 2017, Smith Group Asset Management held 498 positions worth $2.99B, down 8.1% from $3.26B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Smith Group Asset Management withdrew a net $458M in Q3 2017, closing 53 positions and reducing 221 holdings. Its most notable exit was Citrix Systems Inc, an estimated $54.3M position sold in full.

By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 22% a quarter earlier, followed by Consumer Discretionary and Healthcare.

Against the trend, Smith Group Asset Management opened a new position in Procter & Gamble worth $26.9M.

  • Smith Group Asset Management's largest Q3 2017 buy was Procter & Gamble: 295,298 shares worth $26.9M.
  • Smith Group Asset Management added most to Boeing in Q3 2017, an estimated $63.6M increase.
  • Smith Group Asset Management's biggest Q3 2017 reduction was Rockwell Automation, cutting an estimated $28.9M.
  • Smith Group Asset Management fully exited Citrix Systems Inc in Q3 2017, selling an estimated $54.3M.
  • Smith Group Asset Management's ten largest holdings make up 28% of its $2.99B portfolio in Q3 2017.
  • Smith Group Asset Management opened 54 new positions and closed 53 in Q3 2017.
  • Smith Group Asset Management's portfolio value fell 8.1% quarter-over-quarter to $2.99B.

Based on Smith Group Asset Management's 13F filing for Q3 2017, filed 2 Nov 2017.